PDCD1 and small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) such as programmed cell death ligand-1/programmed cell death 1 (PD-L1/PD-1) inhibitors have revolutionized the therapeutic paradigm of SCLC.